IMUX News and Press, Immunic Inc. From 10/01/25

Immunic to Participate in Scientific and Investor Conferences in October PR Newswire NEW YORK , Oct. 1, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule t...

Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis PR Newswire – Vidofludimus Calcium Demonstrated Statistically Significant 24-Week Confirmed Disability Improvement in Phase 2 CALLIPER Trial...

Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dose Strengths in Progressive Multiple Sclerosis PR Newswire – Fifth U.S. Patent Directed to Use of Vidofludimus Calcium in Multiple Sclerosis – – Compr...

Immunic to Participate in Investor and Scientific Conferences in September PR Newswire NEW YORK , Sept. 4, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX) , a biotechnology company developing a clinical pipeline of orally administered, small mo...

Immunic Inc. (IMUX) is expected to report $-0.18 for Q2 2025

2025-08-07 07:58:45 ET More on Immunic Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted Immunic shares fall 12% after pricing of $65 million underwritten public offering to fund trials Immunic launches public offering of warrants to fund c...

Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update PR Newswire – Vidofludimus Calcium Substantially Reduced 24-Week Confirmed Disability Worsening in Phase 2 CALLIPER Trial in Overall Progressive Multiple Sclerosis Study Population...

2025-06-24 07:19:56 ET DENVER, Colo., Jun 24, 2025 ( 247marketnews.com )- Three biotech companies, iBio (NASDAQ:IBIO) , Nektar Therapeutics (NASDAQ:NKTR) , and Immunic (NASDAQ:IMUX) , are stepping into the spotlight this week with pivotal updates. From next-generation obesit...

Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis PR Newswire – At Week 144, 92.3% of Patients Remained Free of 12-Week Confirmed Disability Worsening (CDW) Wit...

2025-06-09 17:51:57 ET What Happened On April 30, 2025, Immunic, Inc. (IMUX) provided a readout from its CALLIPER study investigating Vidofludimus Calcium in progressive MS. Following the readout, the stock tanked more than 20%. The stock has continued to falter since the re...